FDA decision to stop quick review of lab developed tests raises payment concerns for labs |
The agency's decision raises questions around reimbursement and liability protections. It could also impact the ability of new lab-developed tests to compete. That's because an emergency use authorization, which the new tests won't have, are often seen as a mark of quality. |
READ MORE > |
No comments:
Post a Comment